PAF-induced eosinophil chemotaxis increases during an asthmatic attack and is inhibited by prednisolone in vivo and in vitro.
We investigated platelet-activating factor (PAF)-induced migration in eosinophils obtained from asthmatic patients who were treated with or without intravenous prednisolone. The migration of asthmatic eosinophils in remission and during an attack was significantly greater than that in healthy volunteers. The migration of asthmatic eosinophils exposed to prednisolone in vivo and in vitro was significantly inhibited, compared to asthmatic eosinophils not exposed to prednisolone. These findings suggest that an intracellular factor causes asthmatic eosinophils to migrate, and that prednisolone inhibits PAF-induced eosinophil migration.
Shindo
K
K
First Department of Internal Medicine, Yokohama City University School of Medicine, Japan.
Koide
K
K
Fukumura
M
M
D000328:Adult; D000420:Albuterol / Q000494:pharmacology; D001249:Asthma / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D002469:Cell Separation; D002499:Centrifugation, Density Gradient; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D004804:Eosinophils / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology; D010972:Platelet Activating Factor / Q000378:metabolism / Q000494:pharmacology*; D010980:Platelet Membrane Glycoproteins / Q000187:drug effects / Q000502:physiology; D011239:Prednisolone / Q000494:pharmacology* / Q000627:therapeutic use; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D012016:Reference Values
D010972:Platelet Activating Factor; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; C039351:platelet activating factor receptor; D011239:Prednisolone; D000420:Albuterol